medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2018, Número 1

Dermatología Cosmética, Médica y Quirúrgica 2018; 16 (1)


Opciones terapéuticas y preventivas no invasivas para el cáncer de piel no melanoma en pacientes pediátricos con xeroderma pigmentoso

Cheirif-Wolosky O, Palacios-López C

Idioma: Español
Referencias bibliográficas: 47
Paginas: 83-91
Archivo PDF: 163.32 Kb.


RESUMEN

El xeroderma pigmentoso es una enfermedad autosómica recesiva que se caracteriza porque presenta hipersensibilidad cutánea a los rayos ultravioleta (uv) con un riesgo elevado de presentar carcinoma basocelular, carcinoma espinocelular y melanoma desde la infancia. Existen múltiples opciones terapéuticas no invasivas para tratar a estos pacientes. Entre las opciones se encuentran los tratamientos tópicos, algunos de los cuales se han probado en pacientes con xeroderma pigmentoso. Algunas opciones son el imiquimod, el 5-fluorouracilo y el mebutato de ingenol. Para la quimioprevención se utilizan los retinoides sistémicos, y también son parte del tratamiento preventivo los protectores tópicos y sistémicos. Existen otros tratamientos innovadores como la fotoliasa y la endonucleasa t4n5. A continuación revisamos detalladamente cada uno de éstos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. DiGiovanna JJ y Kraemer KH, Shining a light on xeroderma pigmentosum, J Invest Dermatol 2012; 132:785-96.

  2. Black JO, Xeroderma pigmentosum, Head and Neck Pathol 2016; 10:139-44.

  3. Paller AS y Mancini AJ, Xeroderma pigmentoso. En Hurwitz clinical pediatric dermatology, Cambridge, Elsevier 2011, pp. 455-7.

  4. Kraemer KH, Lee MM y Scotto J, Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases, Arch Dermatol 1987; 123:241-50.

  5. Anttinen A, Koulu L, Nikoskelainen E et al., Neurological symptoms and natural course of xeroderma pigmentosum, Brain 2008, 131:1979-89.

  6. Broughton BC, Cordonnier A, Kleijer WJ et al., Molecular analysis of mutations in dna polymerase eta in xeroderma pigmentosum-variant patients, Proc Natl Acad Sci 2002; 99:815-20.

  7. Bradford PT, Goldstein AM, Tamura D et al., Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of adn repair, J Med Genet 2011 48:168-76.

  8. Bunick CG, Miller MR, Fuller BE, Fanning E y Chazin WJ, Biochemical and structural domain analysis of xeroderma pigmentosum complementation group c protein, Biochemistry 2006; 45:14965-79.

  9. Marini F, Nardo T, Giannattasio M et al., dna nucleotide excision repair- dependent signaling to checkpoint activation, Proc Natl Acad Sci 2006; 103:17325-30.

  10. Karass M, Naguib MN, Elawabdeh N et al., Xeroderma pigmentosa: three new cases with an in depth review of the genetic and clinical characteristics of the disease, Fetal and Pediatr Pathol 2015; 34:120-7.

  11. Berneburg M y Lehmann AR, Xeroderma pigmentosum and related disorders: defects in dna repair and transcription, Adv Genet 2001; 43:71-102.

  12. Almutawa F, Vandal R, Wang SQ y Lim HW, Current status of photoprotection by glass by window glass, automobile glass, window films, and sunglasses, Photodermatol Photoimmunol Photomed 2013; 29:65-72.

  13. Jansen R, Wang SQ, Burnett M, Osterwalder U y Lim HW, Photoprotection: part i. Photoprotection by naturally occurring, physical, and systemic agents, J Am Acad Dermatol 2013; 69: 853.

  14. Nakagawara VB, Montgomery RW y Marshall WJ, Optical radiation transmittance of aircraft windscreens and pilot vision, Washington, Federal Aviation Administration, Office of Aerospace Medicine 2007.

  15. Gambichler T, Altmeyer P y Hoffmann K, Role of clothes in sun protection, Recent Results Cancer Res 2002; 160:15-25.

  16. Masaki T, Wang Y, DiGiovanna JJ et al., High frequency of pten mutations in nevi and melanomas from xeroderma pigmentosum patients, Pigment Cell Melanoma Res 2014; 7:454-64.

  17. Nagore E, Sevila A, Sanmartín O et al., Excellent response of basal cell carcicomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream, Br J Dermatol 2003; 149:858-61.

  18. Ocampo-Candiani J, Silva-Siwady G, Fernández-Gutiérrez L y Field L, Dermabrasion in xeroderma pigmentosum, Dermatol Surg 1996; 22(6):575-7.

  19. Yang J, Chen X, Engle M y Wang J, Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream, Dermatol Ther 2015; 28:243-7.

  20. Lear J, Evidence-based treatment for low-risk basal cell carcinoma, Lancet Oncol 2014; 15:12-3.

  21. Arits A, Mosterd K, Essers B et al., Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal- cell carcinoma: a single blind, non-inferiority, randomised controlled trial, Lancet Oncol 2013; 14:647-54.

  22. Tandon Y y Brodell R, Local reactions to imiquimod in the treatment of basal cell carcinoma, Dermatol Online J 2012; 18(9):1.

  23. Weisberg N y Varghese M, Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream, Dermatol Surg 2002; 28:518-23.

  24. Nijsten T, Lapière K y Lambert J, A patient with xeroderma pigmentosum treated with imiquimod 5% cream, J Am Acad Dermatol 2005; 52(1):170-1.

  25. Alessi S, Sanches J, Oliveira W et al., Treatment of cutaneous tumors with topical 5% imiquimod cream, Clinics 2009; 64:961-6.

  26. Hamouda B, Jamila Z, Najet R et al., Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum, J Am Acad Dermatol 2001; 44(6):1054.

  27. Challacombe J, Suhrbier A, Parsons P et al., Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol- 3-angelate, J Immunol 2006; 177:8123-32.

  28. Anderson L, Schmieder G, Werschler W et al., Randomized, double- blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis, J Am Acad Dermatol 2009; 60:934-43.

  29. Slaughter DP, Southwick HW y Smejkal W, Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin, Cancer 1953; 6:963-8.

  30. Peck GL, Digiovanna JJ, Sarnoff DS et al., Treatment and prevention of basal cell carcinoma with oral isotretinoin, J Am Acad Dermatol 1988; 19:176-85.

  31. Giannotti B, Vanzi L, Difonzo EM y Pimpinelli N, The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of 5% imiquimod cream and oral acitretin, Clin Exp Dermatol 2003; 1:33-5.

  32. Kraemer KH, Digiovanna JJ, Moshell AN, Tarone RE y Peck GL, Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin, N Engl J Med 1988; 318:1633-7.

  33. Sun SY y Lotan R, Retinoids and their receptors in cancer development and chemoprevention, Crit Rev Oncol Hematol 2002; 41(1):41-55.

  34. Lambert WC y Lambert MW, Development of effective skin cancer treatment and prevention in xeroderma pigmentosum, Photochemistry and Photobiology 2015; 91:475-83.

  35. Tamura D, Digiovanna JJ, Khan SG y Kraemer KH, Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients, Photodermatol Photoimmunol Photomed 2014; 30:146-52.

  36. Aguilera P, Carrera C, Puig-Butille JA et al., Benefits of oral polypodium leucotomos extract in mm high-risk patients, J Eur Acad Dermatol Venereol 2013; 27:1095-100.

  37. González S, Gilaberte Y y Philips N, Mechanistic insights in the use of a polypodium leucotomos extract as an oral and topical photoprotective agent, Photochem Photobiol Sci 2010; 9:559-63.

  38. Haylett AK, Nie Z, Brownrigg M, Taylor R y Rhodes LE, Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D- Phe7]-Alpha-Msh, Br J Dermatol 2011; 164:407-14.

  39. Harms J, Lautenschlager S, Minder CE y Minder EI, An alpha-melanocyte- stimulating hormone analogue in erythropoietic protoporphyria, N Engl J Med 2009; 360:306-7.

  40. Elmets CA, Viner JL, Pentland AP et al., Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo- controlled trial, J Natl Cancer Inst 2010; 102:1835-44.

  41. Yarosh D, Klein J, O’Connor A et al., Effect of topically applied t4 endonuclease v in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group, Lancet 2001; 357:926-9.

  42. Stege H, Roza L, Vink AA et al., Enzyme plus light therapy to repair dna damage in ultraviolet-b-irradiated human skin, Proc Natl Acad Sci USA 2000; 97:1790-5.

  43. Giustini S, Miraglia E, Berardesca E, Milani M y Calvieri S, Preventive long-term effects of a topical film-forming medical device with ultra- high uv protection filters and dna repair enzyme in xeroderma pigmentosum: a retrospective study of eight cases, Case Rep Dermatol 2014; 6:222-6.

  44. Lim HW, Arellano-Mendoza M y Stengel F, Current challenges in photoprotection, J Am Acad Dermatol 2017; 76:S91-9.

  45. Miyata R, Tanuma N, Sakuma H y Hayashi M, Circadian rhythms of oxidative stress markers and melatonin metabolite in patients with xeroderma pigmentosum group a, Oxidative medicine and cellular longevity 2016; 2016:1-5.

  46. Tang JY, Fu T, Lau C et al., Vitamin d in cutaneous carcinogenesis: part ii, J Am Acad Dermatol 2012; 67:E1-11.

  47. Kuwabara A, Tsugawa N, Tanaka K. et al., High prevalence of vitamin d deficiency in patients with xeroderma pigmentosum: a under strict sun protection, European Journal of Clinical Nutrition 2015; 69(6):693-6.




2020     |     www.medigraphic.com